BERLIN, June 9, 2026 /PRNewswire/ -- Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its...
Hence then, the article about pentixapharm announces fda clearance of ind for phase 3 panda study of first in class cardiovascular diagnostic program was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program )
Also on site :
- I Finally Ordered the Pizza Cupcakes From ‘Shark Tank’—Here’s My Honest Review
- Tech giant OpenAI files for US initial public offering
- I Recreated 5 Viral Y2K Makeup Looks—Here’s What Still Works in 2026